CEO steps down at Oragenics
May 3, 2021 - Dr. Alan Joslyn resigned as chief executive officer, president and director of Oragenics, a Tampa-based biotech firm. Joslyn resigned effective May 2 to pursue other opportunities, according to a news release from the company. Before a new CEO is hired, the board of directors will provide direction to the company, with Dr. Frederick Telling transitioning from chairman of the board to the newly established position of executive chairman, effective immediately. Mike Sullivan, the company’s current chief financial officer, will serve as the company’s interim principal executive officer to address the vacancy created by Joslyn’s resignation. Oragenics recently raised $20 million from the sale of common stock and will use some of the funding to boost its research into a Covid-19 vaccine.